Track NSRX and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$27.32M
Enterprise Value$28.83M
Revenue (TTM)-
Net Income (TTM)-
Free Cash Flow (TTM)-
Financial Health
Cash$284.00K
Net Debt$1.52M
Debt Ratio0.36
Debt to Equity0.65
Interest Coverage-
Valuation (TTM)
Price to Sales-
Price to Earnings-
EV to EBITDA-
Price to Book9.87
Price to Free Cash Flow-
Margins (TTM)
Gross Profit Margin-
EBITDA Margin-
Operating Income Margin-
Net Income Margin-
Free Cash Flow Margin-
Returns (5Y Avg)
Return on Invested Capital-
Return on Assets-
Return on Equity-
Return on Total Capital-
Return on Capital Employed-
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue-
Diluted EPS-
Total Debt-
Capital Expenditures-
Free Cash Flow-
CAGR (3Y)
Revenue-
Diluted EPS-
Total Debt-
Capital Expenditures-
Free Cash Flow-
CAGR (1Y)
Revenue0.00%
Diluted EPS-32.46%
Total Debt0.00%
Capital Expenditures1000.00%
Free Cash Flow-100.00%
$3.03+$0.02|+0.66%
52W High$9.99
52W Low$0.00
50D SMA$3.10
200D SMA$5.02
Volume5.15K
Nasus Pharma Ltd.
Yigal Alon 65, Tel Aviv-Yafo, Israel, 6744317
IPO
2025
Employees
7
Industry
Drug Manufacturers - General
Sector
Healthcare
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Insider Transactions
Quarterly buy vs. sell activity
No insider transactions data available for this period
Analyst Ratings
No coverage data
No analyst ratings data available